Pioglitazone 15/850 mg Tablet (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Adult dosage

The initial dose of this medication should be based on the patient's current treatment regimen. 1. Patients whose blood sugar is not adequately controlled with metformin or pioglitazone monotherapy: It should be based on the current dosage of metformin or pioglitazone they are taking. Start with one tablet of this medication daily and gradually adjust the dosage based on the evaluation of the treatment response. 2. Patients transitioning from combination therapy of pioglitazone and metformin:

This medicine contains two active ingredients, each of which has different precautions to keep in mind. First, one ingredient may cause a rare side effect known as lactic acidosis, which occurs when too much lactic acid builds up in the body and can be life-threatening if severe. The risk is higher in patients with impaired kidney function or those with poor health due to heart disease, infections, etc. Therefore, if symptoms such as dehydration, difficulty breathing, muscle pain, or fatigue occur while taking this medication, immediate consultation with a physician is necessary. Additionally, it is advisable to avoid using this medicine in patients with impaired liver function, and excessive alcohol consumption should be avoided. This medication should be monitored regularly in conjunction with liver and kidney function tests, and extra caution is required in the elderly or those with compromised kidney function. The other ingredient may put stress on the heart and should not be used in patients with heart failure. Use of this medication can lead to fluid retention, resulting in edema or worsening heart failure symptoms, so symptoms such as weight changes, difficulty breathing, and leg swelling should be closely monitored. If any of these symptoms appear, consultation with a physician regarding medication adjustment or discontinuation should be considered. This medicine should not be administered to patients with a history of bladder cancer or those with active bladder cancer. If symptoms such as hematuria, urinary difficulties, or urgency arise during treatment, immediate notification of healthcare personnel is required. Women who are pregnant or nursing should not take this medication, and safety in pediatric patients has not been established. Also, this medicine may interact with other medications, so it is essential to inform your doctor or pharmacist of any other drugs being taken. Special care should be taken when used in conjunction with drugs that affect kidney function. While taking this medication, regular monitoring of blood sugar, blood tests, and kidney and liver function tests is important, and immediate consultation with healthcare personnel is essential if any abnormal symptoms occur. Finally, this medicine may cause hypoglycemia, so it is necessary to avoid skipping meals, excessive exercise, and alcohol consumption, and to respond promptly if hypoglycemic symptoms occur.

Serious side effects

• Blood sugar abnormalities
• lactic acidosis
• severe edema
• congestive heart failure
• heart-related adverse reactions
• liver failure
• sudden and severe headache
• visual disturbances
• paralysis
• hypoxemia

Mild side effects

• Upper respiratory infection
• diarrhea
• nausea
• headache
• urinary tract infection
• sinusitis
• dizziness
• lower limb edema
• weight gain
• muscle pain

Store this medication in a tightly sealed container to protect it from air and moisture, and it is important to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the efficacy and safety of the medication.

Appearance

White to grayish-white rectangular film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)